Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to Trade

Syndax Pharmaceuticals (SNDX) has gained 63.6% in the past four weeks, closing at $16.33, with Wall Street analysts setting a mean price target of $34.75, implying 112.8% upside despite a high standard deviation of $12.74. While analyst price targets are viewed with skepticism, the article highlights a more compelling bullish indicator: a strong consensus among analysts for upward earnings estimate revisions, with the Zacks Consensus Estimate for the current year increasing 11.5% in 30 days. This trend, supported by a Zacks Rank #2 (Buy), suggests legitimate near-term upside for SNDX.

Analysis

Syndax Pharmaceuticals (SNDX) has demonstrated significant upward momentum, with its stock gaining 63.6% over the past four weeks to close at $16.33. While the mean analyst price target of $34.75 implies a substantial 112.8% upside, this figure is accompanied by a high standard deviation of $12.74, indicating considerable variance in analyst opinions and a wide potential range of outcomes from $17.00 to $56.00. The more compelling bullish signal for SNDX is the uniform trend in earnings estimate revisions. Over the last 30 days, the Zacks Consensus Estimate for the current year has risen 11.5%, driven by four upward revisions and zero negative revisions. This strong agreement on improving earnings prospects, which empirical research links to near-term price movements, is further corroborated by the stock's Zacks Rank #2 (Buy). Therefore, the positive outlook for SNDX is less about the headline price target and more about the strengthening fundamental earnings expectations from analysts.

Key Decisions for Investors

• Given the powerfully positive trend in earnings estimate revisions and a corroborating Zacks #2 (Buy) rank, investors could interpret the recent 63.6% price appreciation as fundamentally justified, suggesting the stock may have further near-term upside.
• Investors should treat the mean price target of $34.75 with caution due to the high standard deviation, which signals significant forecast uncertainty and potential for volatility; the wide range of targets suggests the market is awaiting further catalysts.
• It is prudent to focus on the trend of earnings estimate revisions as the primary indicator; a continuation of upward revisions would strengthen the bull case, whereas a stabilization or reversal of this trend could signal a near-term peak.